Something Strange Is Going On At GlaxoSmithKline plc…

GlaxoSmithKline plc’s (LON: GSK) business model has changed, and sales are falling as a result.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

As part of a drive to rebuild its image after the Chinese bribery scandal, GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) announced sweeping changes to the company’s employee compensation plan. 

In an attempt to prevent employees from bribing their way to higher sales figures, Glaxo announced major changes to its sales and marketing practices. Specifically, employees were no longer awarded for hitting or surpassing sales targets. 

At the time, Glaxo’s management hailed this change in strategy, boasting that the company was the first in the pharma industry to change its practices. But now, more than a year on, there are signs that this change has done irreversible damage to Glaxo’s sales and future outlook. 

Increasing competition 

Even though Glaxo decided to change the way it pays staff, almost all of the company’s peers have continued to pay staff using a commission model. And when the company’s revealed this year that US sales were sliding, it didn’t take City analysts long to put two and two together. 

Indeed, some analysts now believe that Glaxo’s US sales staff have lost all of their motivation to sell, as performance is not rewarded, the right incentives are no longer offered. Meanwhile, sales teams working for competitors are still highly motivated.

So all in all, Glaxo is losing market share to more aggressive competitors. 

Cutting costs 

As sales have started to slide, Glaxo’s management has decided to cut costs, in an attempt to maintain profitability and widen margins. Alongside third quarter results, the group announced a £1bn cost-cutting programme that was to take place over the next three years. 

A cost cutting plan is a strange move for a company that only recently:

“… [launched] more new medicines than any other company in the industry in the past 18 months…”

Unfortunately, the bulk of these cost savings will be achieved by slashing the research and development budget. Management has already decided to axe 900 jobs in North Carolina US, around 5% of the company’s total US workforce. Chemists, engineers, biologists, statisticians and clinical development scientists are the main types of jobs to be eliminated.

Glaxo claims that these job cuts are ‘strategic’, in an attempt to reshape the size of the company’s R&D operations, to be more agile to flex with shifting market demands. 

Hefty job cuts, a £1bn restructuring plan and deteriorating sales are concerning. What’s more, it remains to be seen how this round of R&D job cuts will affect Glaxo’s long-term outlook, and ability to compete effectively with rivals.

The bottom line 

Overall, Glaxo tried to change for the better but it seems as if this change has backfired.

Still, for the time being, Glaxo remains an attractive investment but this could change as sales continue to slide. With this in mind, it could payoff to keep an eye on the company and sell if things look like they’re getting worse.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves owns shares of GlaxoSmithKline. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »

Investing Articles

Are HSBC shares a FTSE bargain? Here’s what the charts say!

There are plenty of dirt-cheap FTSE 100 banking stocks for investors to choose from today. Our writer Royston Wild believes…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Just released: Share Advisor’s latest ‘Hold’ recommendation [PREMIUM PICKS]

In our Share Advisor newsletter service, we provide buy, sell, and hold guidance for our universe of recommendations.

Read more »

Investing Articles

Investing £5 a day could help me build a second income of £329 a month!

This Fool explains how £5 a day, or one less takeaway coffee, could help her build a monthly second income…

Read more »

Smart young brown businesswoman working from home on a laptop
Investing Articles

2 FTSE income stocks investors should consider buying in April

Income stocks are a great way to build wealth. Our writer details two picks she believes investors should consider snapping…

Read more »